M&A Science
Sell Side M&A Advice
15 Sep 2017 · 26 mins
Play episode

In 2005, Vamsi started his own company focused on data compliance for the pharmaceutical industry. His company provided technology to support clinical trials to the FDA. “I like to build companies, but I also like change. [After five years], I thought about selling the company and rolling it up into a publicly listed company.” He sold it in 2010 and moved to India to pursue new opportunities. While the sale was smooth, there were numerous post-sale challenges. “They basically ran down the company within 18 months.”


0:00 – 4:03 Vamsi’s background at Deloitte, Pfizer, Merrill Lynch

4:04 – 6:27 Acquiring Clinovo (how found and why chose over others)

6:28 – 9:24 Due diligence process as a buyer

9:25 – 11:24 Issues that came up during diligence process

11:25 – 13:39 Working with the investment banker

13:40 – 14:19 Interaction with seller prior to closing

14:20 – 19:19 Challenges with integration

19:20 – 21:55 Lessons learned and post-closing challenges

21:56 – 23:05 Lessons from the sell side

23:06 – 23:38 What’s on the horizon


M&A Science by Kison Patel (kison@dealroom.net)

DealRoom: Data Science and AI for M&A (www.dealroom.net)

Clear search
Close search
Google apps
Main menu